Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Related to this article
Published phase 1 findings support the promising efficacy and tolerability of anito-cel in relapsed/refractory multiple myeloma, explains lead author Matthew Frigault, MD.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Zabilugene Almadenorepvec Plus Chemo Shows Survival Gains in Metastatic PDAC
2
Telehealth May Offer a Path to More Equitable Myeloma Transplant Access
3
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
4
In CML, Future Directions Include TKI Sequencing Strategies and Mutational Profiles
5